Neuraminidase inhibitors and their role in avian and pandemic influenza.
Identifieur interne : 001A67 ( PubMed/Curation ); précédent : 001A66; suivant : 001A68Neuraminidase inhibitors and their role in avian and pandemic influenza.
Auteurs : Martin Crusat [Viêt Nam] ; Menno D. De JongSource :
- Antiviral therapy [ 1359-6535 ] ; 2007.
Descripteurs français
- KwdFr :
- Animaux, Antienzymes (usage thérapeutique), Antiviraux (usage thérapeutique), Flambées de maladies (), Grippe chez les oiseaux (), Grippe chez les oiseaux (traitement médicamenteux), Grippe chez les oiseaux (virologie), Grippe humaine (), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains, Oiseaux, Oséltamivir (usage thérapeutique), Résistance virale aux médicaments, Sialidase (antagonistes et inhibiteurs), Souris, Sous-type H5N1 du virus de la grippe A (), Sous-type H5N1 du virus de la grippe A (enzymologie), Sous-type H9N2 du virus de la grippe A (), Zanamivir (usage thérapeutique).
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- enzymologie : Sous-type H5N1 du virus de la grippe A.
- traitement médicamenteux : Grippe chez les oiseaux, Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux, Oséltamivir, Zanamivir.
- virologie : Grippe chez les oiseaux.
- épidémiologie : Grippe humaine.
- Animaux, Flambées de maladies, Grippe chez les oiseaux, Grippe humaine, Humains, Oiseaux, Résistance virale aux médicaments, Souris, Sous-type H5N1 du virus de la grippe A, Sous-type H9N2 du virus de la grippe A.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (therapeutic use), Birds, Disease Outbreaks (prevention & control), Drug Resistance, Viral, Enzyme Inhibitors (therapeutic use), Humans, Influenza A Virus, H5N1 Subtype (drug effects), Influenza A Virus, H5N1 Subtype (enzymology), Influenza A Virus, H9N2 Subtype (drug effects), Influenza in Birds (drug therapy), Influenza in Birds (prevention & control), Influenza in Birds (virology), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Mice, Neuraminidase (antagonists & inhibitors), Oseltamivir (therapeutic use), Zanamivir (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors, Oseltamivir, Zanamivir.
- drug effects : Influenza A Virus, H5N1 Subtype, Influenza A Virus, H9N2 Subtype.
- drug therapy : Influenza in Birds, Influenza, Human.
- enzymology : Influenza A Virus, H5N1 Subtype.
- epidemiology : Influenza, Human.
- prevention & control : Disease Outbreaks, Influenza in Birds, Influenza, Human.
- virology : Influenza in Birds.
- Animals, Birds, Drug Resistance, Viral, Humans, Mice.
Abstract
Continuing occurrences of human infections with avian influenza A (H5N1) viruses have ignited increasing fears that the next influenza pandemic is imminent. Fortunately, options for antiviral prophylaxis and treatment have been improved dramatically since the previous pandemics by the availability of neuraminidase inhibitors such as zanamivir and oseltamivir. However, although the prophylactic and therapeutic efficacy of these drugs is well established for uncomplicated seasonal human influenza, clinical effectiveness seems limited for human H5N1 infections despite in vitro susceptibility and efficacy in animal studies. Factors which might contribute to this apparently limited efficacy include suboptimal dosing or routes of administration, suboptimal timing of treatment and the inability of antiviral drugs to interfere with immunopathology, and the development of drug resistance. Efforts to optimize the use of neuraminidase inhibitor treatment in H5N1 disease are urgently needed and might eventually aid in the judicious use of stockpiled neuraminidase inhibitors in the event of a pandemic.
PubMed: 17944267
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A67
Links to Exploration step
pubmed:17944267Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase inhibitors and their role in avian and pandemic influenza.</title><author><name sortKey="Crusat, Martin" sort="Crusat, Martin" uniqKey="Crusat M" first="Martin" last="Crusat">Martin Crusat</name><affiliation wicri:level="1"><nlm:affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.</nlm:affiliation><country xml:lang="fr">Viêt Nam</country><wicri:regionArea>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City</wicri:regionArea></affiliation></author><author><name sortKey="De Jong, Menno D" sort="De Jong, Menno D" uniqKey="De Jong M" first="Menno D" last="De Jong">Menno D. De Jong</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17944267</idno><idno type="pmid">17944267</idno><idno type="wicri:Area/PubMed/Corpus">001A67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A67</idno><idno type="wicri:Area/PubMed/Curation">001A67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuraminidase inhibitors and their role in avian and pandemic influenza.</title><author><name sortKey="Crusat, Martin" sort="Crusat, Martin" uniqKey="Crusat M" first="Martin" last="Crusat">Martin Crusat</name><affiliation wicri:level="1"><nlm:affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.</nlm:affiliation><country xml:lang="fr">Viêt Nam</country><wicri:regionArea>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City</wicri:regionArea></affiliation></author><author><name sortKey="De Jong, Menno D" sort="De Jong, Menno D" uniqKey="De Jong M" first="Menno D" last="De Jong">Menno D. De Jong</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Birds</term><term>Disease Outbreaks (prevention & control)</term><term>Drug Resistance, Viral</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Humans</term><term>Influenza A Virus, H5N1 Subtype (drug effects)</term><term>Influenza A Virus, H5N1 Subtype (enzymology)</term><term>Influenza A Virus, H9N2 Subtype (drug effects)</term><term>Influenza in Birds (drug therapy)</term><term>Influenza in Birds (prevention & control)</term><term>Influenza in Birds (virology)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Mice</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (therapeutic use)</term><term>Zanamivir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Flambées de maladies ()</term><term>Grippe chez les oiseaux ()</term><term>Grippe chez les oiseaux (traitement médicamenteux)</term><term>Grippe chez les oiseaux (virologie)</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Oiseaux</term><term>Oséltamivir (usage thérapeutique)</term><term>Résistance virale aux médicaments</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Souris</term><term>Sous-type H5N1 du virus de la grippe A ()</term><term>Sous-type H5N1 du virus de la grippe A (enzymologie)</term><term>Sous-type H9N2 du virus de la grippe A ()</term><term>Zanamivir (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term><term>Influenza A Virus, H9N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza in Birds</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza in Birds</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe chez les oiseaux</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe chez les oiseaux</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza in Birds</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Birds</term><term>Drug Resistance, Viral</term><term>Humans</term><term>Mice</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Flambées de maladies</term><term>Grippe chez les oiseaux</term><term>Grippe humaine</term><term>Humains</term><term>Oiseaux</term><term>Résistance virale aux médicaments</term><term>Souris</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Sous-type H9N2 du virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Continuing occurrences of human infections with avian influenza A (H5N1) viruses have ignited increasing fears that the next influenza pandemic is imminent. Fortunately, options for antiviral prophylaxis and treatment have been improved dramatically since the previous pandemics by the availability of neuraminidase inhibitors such as zanamivir and oseltamivir. However, although the prophylactic and therapeutic efficacy of these drugs is well established for uncomplicated seasonal human influenza, clinical effectiveness seems limited for human H5N1 infections despite in vitro susceptibility and efficacy in animal studies. Factors which might contribute to this apparently limited efficacy include suboptimal dosing or routes of administration, suboptimal timing of treatment and the inability of antiviral drugs to interfere with immunopathology, and the development of drug resistance. Efforts to optimize the use of neuraminidase inhibitor treatment in H5N1 disease are urgently needed and might eventually aid in the judicious use of stockpiled neuraminidase inhibitors in the event of a pandemic.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17944267</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-6535</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4 Pt B</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>Neuraminidase inhibitors and their role in avian and pandemic influenza.</ArticleTitle><Pagination><MedlinePgn>593-602</MedlinePgn></Pagination><Abstract><AbstractText>Continuing occurrences of human infections with avian influenza A (H5N1) viruses have ignited increasing fears that the next influenza pandemic is imminent. Fortunately, options for antiviral prophylaxis and treatment have been improved dramatically since the previous pandemics by the availability of neuraminidase inhibitors such as zanamivir and oseltamivir. However, although the prophylactic and therapeutic efficacy of these drugs is well established for uncomplicated seasonal human influenza, clinical effectiveness seems limited for human H5N1 infections despite in vitro susceptibility and efficacy in animal studies. Factors which might contribute to this apparently limited efficacy include suboptimal dosing or routes of administration, suboptimal timing of treatment and the inability of antiviral drugs to interfere with immunopathology, and the development of drug resistance. Efforts to optimize the use of neuraminidase inhibitor treatment in H5N1 disease are urgently needed and might eventually aid in the judicious use of stockpiled neuraminidase inhibitors in the event of a pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crusat</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jong</LastName><ForeName>Menno D</ForeName><Initials>MD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>077078/Z/05/Z</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>N01-AO-00042</GrantID><Acronym>AO</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001717" MajorTopicYN="N">Birds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053127" MajorTopicYN="N">Influenza A Virus, H9N2 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005585" MajorTopicYN="N">Influenza in Birds</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>102</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17944267</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001A67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17944267
|texte= Neuraminidase inhibitors and their role in avian and pandemic influenza.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17944267" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |